Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data

By  

ALLERGY, Vol. 73, Iss. 3, 2018-03 ,pp. : 576-584

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series

By  

PEDIATRIC ALLERGY AND IMMUNOLOGY, Vol. 26, Iss. 6, 2015-09 ,pp. : 585-588

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients

By  

THE JOURNAL OF DERMATOLOGY, Vol. 45, Iss. 1, 2018-01 ,pp. : 17-23

John Wiley & Sons Inc

Access to resources Recommend Favorite

D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria

By  

International Archives of Allergy and Immunology, Vol. 172, Iss. 1, 2017-02 ,pp. : 40-44

Karger

Access to resources Recommend Favorite

The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change

By  

ALLERGY, Vol. 73, Iss. 3, 2018-03 ,pp. : 705-712

John Wiley & Sons Inc

Access to resources Recommend Favorite